Source comparison
MOTS-c Protocol Comparison: Dosing Frequencies and Metabolic Outcomes
Baseline Metabolic Support 5mg 3× weekly (M/W/F) AMPK activation, glucose uptake, mitochondrial efficiency 8–12 weeks minimum Phase 2 trial data available Most sustainable long-term protocol. Lowest dose with measurable AMPK response Performance Enhancement 10
This comparison does not assign a generated winner or score.
- Baseline Metabolic Support
- 5mg
- 3× weekly (M/W/F)
- AMPK activation, glucose uptake, mitochondrial efficiency
- 8–12 weeks minimum
- Phase 2 trial data available
- Most sustainable long-term protocol. Lowest dose with measurable AMPK response
- Performance Enhancement
- 10mg
- 2× weekly (spaced 72–96 hours)
- Acute endurance capacity, lactate clearance, ATP synthesis rate
- 4–8 week training blocks
- Observational cohort studies
- Higher acute effect but no evidence of superior long-term adaptation vs 5mg 3× weekly
- Metabolic Dysfunction Support
- 5–10mg
- 3× weekly
- Insulin sensitivity, skeletal muscle glucose disposal, mitochondrial biogenesis
- 12+ weeks
- Preclinical models + human case series
- Requires concurrent dietary intervention. MOTS-c alone insufficient for glycemic control
- Research/Experimental
- 15–20mg
- 1–2× weekly
- Longevity pathways, NAD+ metabolism, oxidative stress markers
- Variable
- Animal models only
- No human safety data above 10mg. Risk of unknown off-target effects